Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE:300497)
China · Delayed Price · Currency is CNY 16.41
+0.11 (0.67%)
Jul 31, 2026, 3:04 PM CST
SHE:300497 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 1,309 | 1,185 | 1,178 | 1,610 | 1,647 | 1,430 |
Revenue Growth | 22.21% | 0.61% | -26.83% | -2.28% | 15.23% | -4.25% |
Gross Profit Gross Profit Growth | 291.53 | 189.82 | 53.88 | 138.32 | 214.38 | 433.36 |
Operating Income Operating Income Growth | 14.21 | -41.1 | -182.48 | -170.12 | -59 | 173.07 |
Net Income Net Income Growth | 3.93 | -55.03 | -272.1 | -200.8 | -141.47 | 48.83 |
Earnings Per Share EPS Growth | 0.01 | -0.10 | -0.51 | -0.37 | -0.26 | 0.09 |
EPS Growth | - | - | - | - | - | -86.96% |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Pharmaceutical Manufacturing Pharmaceutical Manufacturing Growth | 814.22 | 918.01 | 1,321 | 1,390 | 1,430 |
Lithium Battery Electrolyte Additive Lithium Battery Electrolyte Additive Growth | 368.77 | 252.65 | 275.09 | 147.47 | - |
CDMO CDMO Growth | 1.99 | 7.19 | 13.32 | 109.88 | - |
Total Total Growth | 1,185 | 1,178 | 1,610 | 1,647 | 1,430 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 472.32 | 483.93 | 697.54 | 731.56 | 1,028 | 1,423 |
Total Debt Total Debt Growth | 1,616 | 1,651 | 1,605 | 1,627 | 1,418 | 1,002 |
Net Cash (Debt) Net Cash Growth | -1,144 | -1,167 | -907.13 | -895.31 | -389.97 | 421.54 |
Net Cash Growth | - | - | - | - | - | -66.26% |
Net Cash Per Share Net Cash Per Share Growth | -2.10 | -2.12 | -1.70 | -1.65 | -0.72 | 0.78 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 42.7 | 62.67 | 187.64 | -64.76 | -120.85 | 72.32 |
Capital Expenditures CapEx Growth | -149.37 | -224.88 | -141.75 | -242.23 | -459.41 | -679.6 |
Free Cash Flow Free Cash Flow Growth | -106.67 | -162.21 | 45.89 | -306.99 | -580.26 | -607.28 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 22.27% | 16.02% | 4.57% | 8.59% | 13.01% | 30.31% |
Operating Margin | 1.09% | -3.47% | -15.49% | -10.57% | -3.58% | 12.11% |
Pretax Margin | -1.05% | -5.50% | -24.50% | -14.49% | -8.66% | 3.85% |
Profit Margin | 0.30% | -4.64% | -23.10% | -12.47% | -8.59% | 3.42% |
FCF Margin | -8.15% | -13.69% | 3.90% | -19.07% | -35.23% | -42.48% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 2248.50 | - | - | - | - | 181.99 |
Forward PE | 12.72 | 29.64 | 29.64 | 29.64 | 29.64 | 19.92 |
P/FCF Ratio | - | - | 97.89 | - | - | - |
PS Ratio | 6.75 | 6.87 | 3.81 | 3.13 | 4.32 | 6.22 |